Trastuzumab-induced cardiotoxicity is a frequent but generally mild adverse event, highlighting the need for further studies to define risk and protective factors.
TIC is a frequent, albeit generally mild, adverse event in clinical practice. Further studies are warranted to better define the risk of and protective factors for TIC.
Farolfi et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: